Plato Investment Management Ltd Has $690,000 Holdings in Insulet Co. (NASDAQ:PODD)

Plato Investment Management Ltd cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 35.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,968 shares of the medical instruments supplier’s stock after selling 1,651 shares during the period. Plato Investment Management Ltd’s holdings in Insulet were worth $690,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. QRG Capital Management Inc. bought a new stake in shares of Insulet in the third quarter worth $297,000. Diversified Trust Co grew its stake in shares of Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after purchasing an additional 4,348 shares during the last quarter. Natixis bought a new stake in shares of Insulet in the first quarter worth $3,610,000. Intech Investment Management LLC grew its stake in shares of Insulet by 113.8% in the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after purchasing an additional 3,539 shares during the last quarter. Finally, Seven Eight Capital LP bought a new stake in shares of Insulet in the first quarter worth $1,418,000.

Insulet Trading Down 2.9 %

PODD opened at $261.16 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The firm has a market capitalization of $18.32 billion, a PE ratio of 44.72, a P/E/G ratio of 4.11 and a beta of 1.22. The company’s 50-day moving average is $236.86 and its 200 day moving average is $206.85.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. UBS Group upped their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. BTIG Research upped their price target on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Morgan Stanley upped their price target on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Barclays upped their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.